Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 808 entries
View as:

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT01226420 Org: User:
Start: 10/31/10 End: 08/31/12 Due: 08/31/13

Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT02400437 Org: User:
Start: 04/30/15 End: 11/30/19 Due: 11/30/20

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00137774 Org: User:
Start: 11/30/04 End: 12/31/12 Due: 12/31/13

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

Phase: N/A Priority: Normal
NCT ID: NCT00047281 Org: User:
Start: 03/31/04 End: 02/28/06 Due: 02/28/07

A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03051659 Org: User:
Start: 03/22/17 End: 09/05/23 Due: 09/05/24

Pilot Study for Young Women's Intervention

Phase: N/A Priority: Normal
NCT ID: NCT01647594 Org: User:
Start: 03/31/11 End: 07/31/12 Due: 07/31/13

Early Interventional Treatment for Cancer Pain

Phase: N/A Priority: Normal
NCT ID: NCT05366413 Org: User:
Start: 06/02/22 End: 10/26/24 Due: 10/26/25

Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: the SOLAR Trial

Phase: N/A Priority: Normal
NCT ID: NCT04883671 Org: User:
Start: 12/27/21 End: 06/01/30 Due: 06/01/31

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Phase: N/A Priority: Normal
NCT ID: NCT03735446 Org: User:
Start: 01/18/19 End: 03/29/19 Due: 03/29/20

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00165399 Org: User:
Start: 03/31/04 End: 12/31/05 Due: 12/31/06

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Phase: N/A Priority: Normal
NCT ID: NCT02326974 Org: User:
Start: 01/31/15 End: 01/31/28 Due: 01/31/29

A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00134706 Org: User:
Start: 01/31/04 End: 09/30/09 Due: 09/30/10

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Phase: N/A Priority: Normal
NCT ID: NCT01366092 Org: User:
Start: 07/31/11 End: 12/31/25 Due: 12/31/26

A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

Phase: N/A Priority: Normal
NCT ID: NCT02135133 Org: User:
Start: 06/30/14 End: 10/06/20 Due: 10/06/21

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Phase: N/A Priority: Normal
NCT ID: NCT03341936 Org: User:
Start: 03/15/18 End: 07/06/26 Due: 07/06/27

Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00317603 Org: User:
Start: 01/01/06 End: 06/30/21 Due: 06/30/22

SHARE (Sharing Goals and Preferences) Study

Phase: N/A Priority: Normal
NCT ID: NCT03392090 Org: User:
Start: 07/23/18 End: 03/15/22 Due: 03/15/23

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03654716 Org: User:
Start: 11/01/18 End: 07/17/23 Due: 07/17/24

Multiple Risk Behavior Intervention in Health Care Settings

Phase: N/A Priority: Normal
NCT ID: NCT01415492 Org: User:
Start: 03/31/09 End: 01/31/12 Due: 01/31/13

GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00426205 Org: User:
Start: 06/30/04 End: 09/30/09 Due: 09/30/10

A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01858688 Org: User:
Start: 09/30/13 End: 04/30/23 Due: 04/30/24

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Phase: N/A Priority: Normal
NCT ID: NCT02287428 Org: User:
Start: 11/30/14 End: 06/30/26 Due: 06/30/27

Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals

Phase: N/A Priority: Normal
NCT ID: NCT03736746 Org: User:
Start: 11/16/18 End: 08/02/19 Due: 08/02/20

CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT02756390 Org: User:
Start: 12/31/15 End: 05/14/18 Due: 05/14/19

Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate

Phase: N/A Priority: Normal
NCT ID: NCT01319591 Org: User:
Start: 03/31/11 End: 09/01/17 Due: 09/01/18